The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying
Substance-use disorders Pre-clinical and mechanistic studies A large body of pre-clinical and mechanistic literature is available regarding the putative effects of GLP-1RAs on substance misuse (Supplementary Section 5): 24 for alcohol 59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82 , 8 for opiates 63,83,84,85,86,87,88,89 , 16 for stimulants, including cocaine and amphetamines 90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105 , and 4 for nicotine 106,107,108,109
Navigators link patients to community resources, to national resources
Third, although existing studies consistently demonstrate beneficial effects on hepatic steatosis and inflammation, the lack of head-to-head mechanistic and biomarker-based comparisons restricts the ability to distinguish between different GLP-1RAs or combination therapies in terms of their molecular pathways, immunemetabolic regulatory efficiency, and predictive biomarkers of therapeutic response
Find Balance